A rapid chromatographic immunoassay for the qualitative detection and differentiation of IgG and IgM antibodies to SARS-CoV-2 in human venous whole blood, serum or plasma, or fingerstick whole blood. The test is intended for use as an aid in identifying individuals with adaptive immune response to SARS-CoV-2, indicating recent or prior infection. CLIA waived.ARTIST: Add these two lines to first part of note (NOTE field is too large)This test has not been FDA cleared or approved.This test is authorized by FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories only.